Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee


  • 2,250 25 sep 2023 17:31
  • 0,000 (0,00%) Dagrange 2,215 - 2,300
  • 10.678 Gem. (3M) 27,5K

Relief therapeutics Holding

9.102 Posts
Pagina: «« 1 ... 451 452 453 454 455 456 »» | Laatste | Omlaag ↓
  1. forum rang 10 DeZwarteRidder 2 januari 2023 13:25
    Pursuant to a Share Subscription Facility agreement (SSF),

    GEM committed to provide up to CHF 50 million to RELIEF

    THERAPEUTICS Holding SA in exchange for registered shares of

    RELIEF THERAPEUTICS Holding SA in the period from

    January 20, 2021, to January 20, 2024, at the discretion of

    RELIEF THERAPEUTICS Holding SA, subject to certain

    exceptions and limitations. No drawdowns have been made

    until December 19, 2022,resulting in a remaining balance of

    the full amount under the SSF of CHF 50 million. GEM's

    purchase position has been calculated using the closing

    price of the registered shares of RELIEF THERAPEUTICS

    Holding SA on SIX Swiss Exchange on December 19, 2022 (CHF

    0.0288) and applying the 10% discount agreed in the SSF

    (resulting in a share price of CHF 0.02592), by dividing the

    remaining balance under the SSF of CHF 50 million by such

    share price of CHF 0.02592. However, according to the

    terms of the SSF, future subscription prices under the SSF

    will correspond to 90% of the average of the closing bid

    prices on SIX Swiss Exchange during the relevant reference

    period, which corresponds to 15 trading days following

    RELIEF THERAPEUTICS Holding SA's relevant subscription

    request, subject to certain exceptions and limitations.

    Therefore, note that the actual subscription price at which

    GEM may be requested to subscribe for registered shares

    of RELIEF THERAPEUTICS Holding SA under the SSF may be lower

    or higher than the share price applied above, and

    accordingly, the number of voting rights GEM may acquire as

    a result thereof may be higher or lower than as set

    forth in this disclosure.
  2. forum rang 10 DeZwarteRidder 5 mei 2023 11:58
    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
    03.05.2023 / 07:00 CET/CEST

    Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares

    GENEVA (May 3, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the implementation timeline for the reverse split of its ordinary shares, which was approved by shareholders at the Extraordinary General Meeting held on April 28, 2023.

    May 4, 2023: Last trading day of old shares on SIX Swiss Exchange
    May 5, 2023: First trading day of new shares on SIX Swiss Exchange

    As previously communicated, shareholdings will be rounded down to the next lower whole number of new merged shares by applying the 400 to 1 exchange ratio. The resulting fractions will be compensated in cash at a fixed price corresponding to the three-day volume-weighted average price of the Relief Therapeutics share on the SIX Swiss Exchange prior to the reverse split.

    Additional information on the reverse split is provided in a Q&A list available here.


    Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics’ portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ drug delivery platform technologies and a highly targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Our mission to provide therapeutic relief to those suffering from rare diseases is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Rome. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, please visit our website or follow Relief Therapeutics on LinkedIn and Twitter
9.102 Posts
Pagina: «« 1 ... 451 452 453 454 455 456 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum


Koers 2,250   Verschil 0,00 (0,00%)
Laag 2,215   Volume 10.678
Hoog 2,300   Gem. Volume 27.453
25 sep 2023 17:31
Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en tips?

Neem nu een abonnement op IEX en krijg toegang tot onze koop-en verkooptips!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links